Recent events
Recent events tied to this brand in public sources.
Back to profile6 entries
2026
FDA approves Ryzumvi for adult presbyopia
The US Food and Drug Administration approved Viatris’ Ryzumvi to treat presbyopia in adults.
2026
Viatris acquires Pacira BioSciences for $1.65 billion
Viatris Inc. has acquired Pacira BioSciences, Inc.'s outstanding common stock shares for $36.50 per share in cash, in a $1.65 billion transaction. Law firm Ashurst Perkins Coie, which served as main counsel throughout the transaction process, advised Pacira. Viatris plans to extend product lifecycles, sustain meaningful sales, and expand the Pacira products' reach across select markets within its global infrastructure.
2022
Biocon Biologics announces acquisition of Viatris biosimilars business
Biocon Biologics announced a definitive agreement to acquire Viatris' biosimilars business and related assets. The transaction was expected to close in the second half of 2022, subject to closing conditions, including certain regulatory approvals.
2021
Viatris donates $1 million to SBP's Got Your Back Fund
Viatris announced a $1 million donation to SBP, with the partnership focused primarily on SBP's Got Your Back Fund, which supports post-disaster housing for low-to-moderate income U.S. veterans.
2021
Viatris and The Defeat-NCD Partnership sign cooperation MoU
Viatris and The Defeat-NCD Partnership at UNITAR signed an MoU for continued cooperation and joint use of resources on programmes and initiatives addressing non-communicable diseases and their impacts on patients as a result of COVID-19.
2020
Viatris announces details of global restructuring
Viatris announced additional details of its multi-year global restructuring initiative, including plans to close, downsize or divest up to 15 manufacturing facilities and the expectation that up to 20% of its global workforce may be affected upon completion. The announced actions were plans, with workforce reductions at the named sites expected to occur in phases over the next few years.